Regeneron Pharmaceuticals Inc. Stock Advances 13.3%, Outperforms Peers
Dow Jones2026/10/30 20:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. climbed 13.3% to $927.89 on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.8% to 7,580.07 and Dow Jones Industrial Average falling 1.1% to 51,770.31.
This was the stock's second consecutive day of gains.
Regeneron Pharmaceuticals Inc. hit a new 52-week high, surpassing its previous peak of $859.34, which the company reached on September 3rd.
The stock outperformed some of its peers, as Amgen Inc. rose 1.1% to $466.01, Moderna Inc. fell 0.5% to $221.72, and Gilead Sciences Inc. rose 3.06% to $170.68.
Trading volume totaled 2.8 million, compared to the 50-day average of 687,250.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 30, 2026 16:33 ET (20:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Catalysts Cramer Says Could Extend the Nasdaq Sell-Off This Week
Meta (META.US) AI shopping assistant Muse tests e-commerce, Amazon (AMZN.US) faces potential impact on nearly $70 billion advertising business
Meta Platforms (META.US) has launched its new AI shopping assistant, Muse, which is emerging as a potential threat to Amazon. Muse may challenge the e-commerce giant’s dominance in online shopping and its nearly 70 billion USD advertising business.
Crypto prices
More
